Acorda Therapeutics, Inc.
ACORDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001008848
Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.
Holders of 5% or more of ACOR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Acorda Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Acorda Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
20 Schedule 13D and 13G filings on Acorda Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 10, 2023 | Davidson Kempner Capital Management LP | 13D/AOld format | – | – | – | SEC |
| Mar 10, 2023 | Davidson Kempner Capital Management LP | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Canyon Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2023 | Renaissance Technologies LLC | 13G/AOld format | – | – | – | SEC |
| Jan 23, 2023 | Davidson Kempner Capital Management LP | 13D/AOld format | – | – | – | SEC |
| Jun 10, 2022 | Soros Fund Management LLCSuperinvestorSoros Fund Management | 13GOld format | – | New | – | SEC |
| Jun 10, 2022 | Davidson Kempner Capital Management LP | 13DOld format | – | New | – | SEC |
| Feb 14, 2022 | UBS Oconnor LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Canyon Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Renaissance Technologies LLC | 13G/AOld format | – | – | – | SEC |
| Apr 28, 2021 | Canyon Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | UBS Oconnor LLC | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Canyon Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Dimensional Fund Advisors LP | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Symphony Asset Management LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Renaissance Technologies LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 20212:49 PM ET | Federated Hermes, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 202112:46 PM ET | Federated Hermes, Inc. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Acorda Therapeutics, Inc. shares.
No Form 144 notices for Acorda Therapeutics, Inc. are on file.